Founded
2018
CEO
Tom Anderson
Founders
Florian Eichler
Rachel Salzman
Karen Kozarsky
% Shareholding
75%
Stage
Pre-clinical
Number of employees
40+
Raised in an expanded Series A in April 2020
$77m

Unless stated all financials at 30 September 2021

Swanbio website

SwanBio Therapeutics is a gene therapy company developing leading-edge medicines to deliver dramatic clinical efficacy for the treatment of genetically defined neurological conditions.

SwanBio Therapeutics is dedicated to developing genetic medicines for the treatment of serious neurological diseases with significant unmet need.

Founded in partnership with industry leaders with a commitment to positively impacting the lives of people with neurological diseases, SwanBio merges clinical, scientific and drug commercialisation expertise.

SwanBio is using adeno-associated viruses (AAVs) to deliver therapeutic genes directly to the central nervous system to achieve profound therapeutic effects. Clinical studies have shown AAVs can be promising vectors for delivering therapeutic DNA and have been shown to be safe and effective in multiple clinical trials, including in other neurological disorders.

SwanBio is developing an AAV-based gene therapy for a rare inherited neurodegenerative disease in which the causative gene is definitively known and well characterised. While their initial focus is on diseases that are both rare and serious, the broader vision is understanding the origin and treatment of disorders where therapeutic DNA has the potential to treat a range of neurological illnesses.

Investment opportunity

  • Gene therapy has the potential be transformational in neurology
  • Lead programme targeting Adrenomyeloneuropathy (AMN), an inherited neurodegenerative disease in which the causative gene is definitively known and well characterised
  • One-off delivery mechanism and multiple tractable pipeline programmes

Unmet medical need

  • Hundreds of single gene neurological disorders with poor or no treatment options
  • Lead programme targeting one of the most common monogenic neurological disorders, a severely debilitating progressive movement disorder with no available therapies

Market opportunity*

  • AMN impacts 8,000-10,000 male patients in the US and EU5

Key risks

  • Slowly progressing disease
  • Complex manufacturing

 

* SwanBio analysis

 

The SwanBio Therapeutics pipeline

Research Pre-clinical Clinical
  • SBT101-Adrenomyeloneuropathy (AMN)

  • Multiple undisclosed research programmes

Syncona team

Chris Hollowood

Chris Hollowood

Chris is the Chief Investment Officer of Syncona Investment Management Ltd. He has been instrumental in the foundation and development of Syncona's gene therapy strategy, where it has founded companies focused on the eye, the liver, the kidney, and central nervous system. He is Chairman of Freeline, Gyroscope, SwanBio and Purespring and was also previously Chairman of Nightstar, a retinal gene the…
View Chris' biography
Position
Chair
Qualification
PhD
Alex Hamilton

Alex Hamilton

Alex is a Partner of Syncona Investment Management Ltd. He is a Director on the Board of SwanBio Therapeutics. Previously, he was a member of the Healthcare Investment Banking team at Jefferies, where he worked on a range of financings and mergers and acquisitions across the biotechnology, pharmaceutical and healthcare sectors. Alex has a PhD in Immunology from the University of Cambridge.
View Alex's biography
Position
Board member
Qualification
PhD

SwanBio Therapeutics leaders and founders

Other gene therapy portfolio companies